Immunosuppression for connective tissue disease-related pulmonary disease

Seminars in Respiratory and Critical Care Medicine

Volumn 35, Issue 2, 2014, Pages 265-273

  Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cyclophosphamide; interstitial lung disease; polymyositis; pulmonary vasculitis; rituximab; systemic sclerosis; therapy

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; GLUCOCORTICOID;

ARTICLE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KNOWLEDGE BASE; LUNG COMPLICATION; LUNG DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; COMPLICATION; DISEASE COURSE; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84897036635     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1371531     Document Type: Article

References (102)

1. Tyndall A. J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis: 2010; 69 10 1809 1815
2. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet: 2012; 380 9842 689 698
3. Kim E. J., Collard H. R., King T. E. Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest: 2009; 136 5 1397 1405
4. Fischer A., Swigris J. J., du Bois R. M., et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med: 2009; 103 11 1719 1724
5. Hoyles R. K., Ellis R. W., Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum: 2006; 54 12 3962 3970 (Pubitemid 44955900)
6. Tashkin D. P., Elashoff R., Clements P. J., et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med: 2006; 354 25 2655 2666
7. Khanna D., Brown K. K., Clements P. J., et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol: 2010; 28 2 58 S55 S62
8. Walker K. M., Pope J.; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum: 2012; 42 1 42 55
9. Launay D., Humbert M., Berezne A., et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest: 2011; 140 4 1016 1024
10. Opitz C., Klein-Weigel P. F., Riemekasten G. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa: 2011; 40 1 20 30
11. Devouassoux G., Cottin V., Lioté H., et al. Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERMOP). Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J: 2009; 33 5 1053 1061
12. Magnusson J., Westin J., Andersson L. M., Brittain-Long R., Riise G. C. The impact of viral respiratory tract infections on long-term morbidity and mortality following lung transplantation: a retrospective cohort study using a multiplex PCR panel. Transplantation: 2013; 95 2 383 388
13. Gregson A. L., Wang X., Weigt S. S., et al. Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation. Am J Respir Crit Care Med: 2013; 187 5 518 526
14. Vos R., Vanaudenaerde B. M., Ottevaere A., et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant: 2010; 29 12 1358 1368
15. Abbassi-Ghadi N., Kumar S., Cheung B., et al. Anti-reflux surgery for lung transplant recipients in the presence of impedance-detected duodenogastroesophageal reflux and bronchiolitis obliterans syndrome: a study of efficacy and safety. J Heart Lung Transplant: 2013; 32 6 588 595
16. Tansey D., Wells A. U., Colby T. V., et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology: 2004; 44 6 585 596 (Pubitemid 38845105)
17. Kowal-Bielecka O., Landewé R., Avouac J., et al. EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis: 2009; 68 5 620 628
18. Ando K., Motojima S., Doi T., et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Investig: 2013; 51 2 69 75
19. Gordon P. A., Winer J. B., Hoogendijk J. E., Choy E. H. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev: 2012; 8 CD003643
20. Kotani T., Makino S., Takeuchi T., et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol: 2008; 35 2 254 259 (Pubitemid 351284439)
21. Connors G. R., Christopher-Stine L., Oddis C. V., Danoff S. K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest: 2010; 138 6 1464 1474
22. Lazor R., Vandevenne A., Pelletier A., Leclerc P., Court-Fortune I., Cordier J. F. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles Orphelines Pulmonaires (GERMOP). Am J Respir Crit Care Med: 2000; 162 (2 Pt 1): 571 577
23. Wells A. U., Latsi P., McCune W. J. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? Am J Respir Crit Care Med: 2007; 176 10 952 953 (Pubitemid 350127836)
24. Domiciano D. S., Bonfá E., Borges C. T., et al. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol: 2011; 30 2 223 229
25. Broad K., Pope J. E. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit: 2010; 16 9 RA187 RA190
26. Wanchu A., Suryanaryana B. S., Sharma S., Sharma A., Bambery P. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis: 2009; 12 3 239 242
27. Bérezné A., Ranque B., Valeyre D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol: 2008; 35 6 1064 1072 (Pubitemid 351813153)
28. White B., Moore W. C., Wigley F. M., Xiao H. Q., Wise R. A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med: 2000; 132 12 947 954 (Pubitemid 30397594)
29. Poormoghim H., Moradi Lakeh M., Mohammadipour M., Sodagari F., Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int: 2012; 32 8 2431 2444
30. Mittoo S., Wigley F. M., Wise R. A., Woods A., Xiao H., Hummers L. K. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J: 2011; 5 1 6
31. Tochimoto A., Kawaguchi Y., Hara M., et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol: 2011; 21 3 296 301
32. Theodore A. C., Tseng C. H., Li N., Elashoff R. M., Tashkin D. P. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest: 2012; 142 3 614 621
33. Roth M. D., Tseng C. H., Clements P. J., et al. Scleroderma Lung Study Research Group. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum: 2011; 63 9 2797 2808
34. Dheda K., Lalloo U. G., Cassim B., Mody G. M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol: 2004; 23 4 306 309 (Pubitemid 39193785)
35. Bodolay E., Szekanecz Z., Dévényi K., et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford): 2005; 44 5 656 661 (Pubitemid 41487239)
36. Okada M., Suzuki K., Matsumoto M., et al. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases. Mod Rheumatol: 2007; 17 2 131 136 (Pubitemid 46614357)
37. Corte T. J., Ellis R., Renzoni E. A., et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis: 2009; 26 2 132 138
38. Goh N. S., Desai S. R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med: 2008; 177 11 1248 1254 (Pubitemid 351860934)
39. Jayne D. Treating vasculitis with conventional immunosuppressive agents. Cleve Clin J Med: 2012; 79 03 S46 S49
40. Casian A., Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med: 2011; 32 3 335 345
41. Schwarz M. I., Zamora M. R., Hodges T. N., Chan E. D., Bowler R. P., Tuder R. M. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease. Chest: 1998; 113 6 1609 1615 (Pubitemid 28307167)
42. Cordier J. F., Cottin V. Alveolar hemorrhage in vasculitis: primary and secondary. Semin Respir Crit Care Med: 2011; 32 3 310 321
43. Lynch J. P. III, Tazelaar H. Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment. Semin Respir Crit Care Med: 2011; 32 3 274 297
44. Stone J. H., Merkel P. A., Spiera R., et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med: 2010; 363 3 221 232
45. Paone C., Chiarolanza I., Cuomo G., et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol: 2007; 25 4 613 616 (Pubitemid 47455470)
46. Yu K. H., Wu Y. J., Kuo C. F., et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol: 2011; 30 12 1595 1601
47. Chung L., Liu J., Parsons L., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest: 2010; 138 6 1383 1394
48. Johnston A., Gudjonsson J. E., Sigmundsdottir H., Ludviksson B. R., Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol: 2005; 114 2 154 163 (Pubitemid 40082381)
49. Smolen J. S., Landewé R., Breedveld F. C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis: 2013
50. Atzeni F., Boiardi L., Sallì S., Benucci M., Sarzi-Puttini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol: 2013; 9 7 649 657
51. Roubille C., Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum: 2013
52. Sathi N., Chikura B., Kaushik V. V., Wiswell R., Dawson J. K. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol: 2012; 31 1 79 83
53. Coppo P., Clauvel J. P., Bengoufa D., Oksenhendler E., Lacroix C., Lassoued K. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology (Oxford): 2002; 41 9 1040 1046
54. Kim P., Grossman J. M. Treatment of mixed connective tissue disease. Rheum Dis Clin North Am: 2005; 31 3 549 565, viii (Pubitemid 41111555)
55. Vanthuyne M., Blockmans D., Westhovens R., et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol: 2007; 25 2 287 292 (Pubitemid 46851433)
56. Simeón-Aznar C. P., Fonollosa-Plá V., Tolosa-Vilella C., Selva-O'Callaghan A., Solans-Laqué R., Vilardell-Tarrés M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol: 2011; 30 11 1393 1398
57. Koutroumpas A., Ziogas A., Alexiou I., Barouta G., Sakkas L. I. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol: 2010; 29 10 1167 1168
58. Gerbino A. J., Goss C. H., Molitor J. A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest: 2008; 133 2 455 460 (Pubitemid 351272405)
59. Swigris J. J., Olson A. L., Fischer A., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest: 2006; 130 1 30 36 (Pubitemid 44116838)
60. Fischer A., Brown K. K., Du Bois R. M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol: 2013; 40 5 640 646
61. Tzouvelekis A., Galanopoulos N., Bouros E., et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med: 2012; 2012 143637
62. Labirua-Iturburu A., Selva-O'Callaghan A., Martínez-Gómez X., Trallero-Araguás E., Labrador-Horrillo M., Vilardell-Tarrés M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol: 2013; 31 3 436 439
63. Matsuki Y., Yamashita H., Takahashi Y., et al. Diffuse alveolar damage in patients with dermatomyositis: a six-case series. Mod Rheumatol: 2012; 22 2 243 248
64. Ando M., Miyazaki E., Yamasue M., et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol: 2010; 29 4 443 445
65. Polosa R., Edwards C. J. Tacrolimus for antisynthetase syndrome with interstitial lung disease? Eur Respir J: 2008; 32 1 244 245, author reply 245-246
66. Guglielmi S., Merz T. M., Gugger M., Suter C., Nicod L. P. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J: 2008; 31 1 213 217
67. Ochi S., Nanki T., Takada K., et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol: 2005; 23 5 707 710 (Pubitemid 41300719)
68. Oddis C. V., Sciurba F. C., Elmagd K. A., Starzl T. E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet: 1999; 353 9166 1762 1763 (Pubitemid 29240378)
69. Cavagna L., Caporali R., Abdì-Alì L., Dore R., Meloni F., Montecucco C. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol: 2013; 40 4 484 492
70. Leandro M. J., Cambridge G., Ehrenstein M. R., Edwards J. C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum: 2006; 54 2 613 620 (Pubitemid 43228639)
71. Isaacs J. D., Cohen S. B., Emery P., et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis: 2013; 72 3 329 336
72. Keystone E. C., Cohen S. B., Emery P., et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol: 2012; 39 12 2238 2246
73. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum: 2006; 54 5 1390 1400
74. Jones R. B., Tervaert J. W., Hauser T., et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med: 2010; 363 3 211 220
75. Arnold D. M., Dentali F., Crowther M. A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med: 2007; 146 1 25 33 (Pubitemid 351650318)
76. Daoussis D., Liossis S. N., Tsamandas A. C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol: 2012; 30 2 71 S17 S22
77. Daoussis D., Liossis S. N., Tsamandas A. C., et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum: 2010; 40 2 127 136
78. Keir G. J., Maher T. M., Hansell D. M., et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J: 2012; 40 3 641 648
79. Keir G. J., Maher T. M., Ming D., et al. Rituximab in severe, treatment-refractory interstitial lung disease [published online ahead of print November 29, 2013]. Respirology. doi: 10.1111/resp.12214
80. Giuggioli D., Manfredi A., Colaci M., Manzini C. U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev: 2013; 12 11 1058 1063
81. Braun-Moscovici Y., Butbul-Aviel Y., Guralnik L., et al. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience. Rheumatol Int: 2013; 33 6 1495 1504
82. Daniels C. E., Wilkes M. C., Edens M., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest: 2004; 114 9 1308 1316 (Pubitemid 40385302)
83. Sabnani I., Zucker M. J., Rosenstein E. D., et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford): 2009; 48 1 49 52
84. Spiera R. F., Gordon J. K., Mersten J. N., et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis: 2011; 70 6 1003 1009
85. Khanna D., Saggar R., Mayes M. D., et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum: 2011; 63 11 3540 3546
86. Distler J. H., Manger B., Spriewald B. M., Schett G., Distler O. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum: 2008; 58 8 2538 2542
87. De Lauretis A., Sestini P., Pantelidis P., et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol: 2013; 40 4 435 446
88. Liu X., Das A. M., Seideman J., et al. The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. Am J Respir Cell Mol Biol: 2007; 37 1 121 128 (Pubitemid 46999544)
89. Moodley Y. P., Scaffidi A. K., Misso N. L., et al. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol: 2003; 163 1 345 354 (Pubitemid 36759619)
90. Yoshida M., Sakuma J., Hayashi S., et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A: 1995; 92 21 9570 9574
91. Keidel S. M., Hoyles R. K., Wilkinson N. M. Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra. Rheumatology (Oxford): 2013
92. Mohr M., Jacobi A. M. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol: 2011; 40 5 400 401
93. Thompson B., Corris P., Miller J. A., Cooper R. G., Halsey J. P., Isaacs J. D. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol: 2008; 35 10 2080 2082
94. Horai Y., Miyamura T., Shimada K., et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther: 2012; 37 1 117 121
95. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum: 2011; 41 2 256 264
96. Ramos-Casals M., Brito-Zerón P., Muñoz S., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore): 2007; 86 4 242 251 (Pubitemid 47067483)
97. Park J. K., Yoo H. G., Ahn D. S., Jeon H. S., Yoo W. H. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int: 2012; 32 11 3587 3590
98. Zong M., Dorph C., Dastmalchi M., et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis: 2013
99. Furlan A., Botsios C., Ruffatti A., Todesco S., Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. Joint Bone Spine: 2008; 75 3 366 367
100. Douglas W. W., Tazelaar H. D., Hartman T. E., et al. Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med: 2001; 164 7 1182 1185 (Pubitemid 33052247)
101. Suzuki Y., Hayakawa H., Miwa S., et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung: 2009; 187 3 201 206
102. Bakewell C. J., Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest: 2011; 139 2 441 443